Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark – Novo Nordisk today ...
Why T-Mobile Is Trouncing Telecom—and Big Tech
A government blunder and TV woes have helped lift the company’s stock 54% in the past year. How to play it now.